S. Korea To Invest $4.5 Billion In Two Medical R&D Centers
This article was originally published in PharmAsia News
Executive SummaryThe South Korean government plans to invest more than $4.5 billion in a pair of industrial clusters dedicated to medical research for innovative drugs, medical devices and clinical trials. The government goal is to have the two medical hubs constructed by 2012 and capable of developing 16 types of drugs and 18 types of devices over 30 years. The Ministry for Health, Welfare and Family Affairs said the investment would pay for itself by creating centers that would generate more than $66 billion worth of medical services, spin-offs and jobs. (Click here for more
You may also be interested in...
MDSAP And USMCA: 3 Ways Mexico Can To Come Up-To-Speed With The Single-Audit Program Targeted By New Free-Trade Accord
The US-Mexico-Canada (USMCA) treaty calls for the three countries to “recognize audits” performed under the Medical Device Single Audit Program. MDSAP is already used by device makers in the US and Canada so they can undergo one audit by an accredited third party to satisfy quality regulations. That leaves Mexico as the odd country out when it comes to using the popular program – and that means it has some catching up to do after the USMCA is ratified by all three nations. Former longtime FDA official Kim Trautman weighs in on how Mexico can incorporate MDSAP into its regulatory framework.
Genomic profiling firm Foundation Medicine hires new chief commercial officer; Bardy Diagnostics, developer of cardiac arrhythmia devices, picks a chief operating officer; Lantheus Medical Imaging, producer of diagnostic imaging agents and products; brings aboard a new chief medical officer; and more.